SP
TNGX icon

Stonebrook Private’s Tango Therapeutics TNGX Stock Holding History

Stonebrook Private’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,992
Closed -$34K – 196
2024
Q4 		$34K Buy
+10,992
New +$51K 0.01% 180

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Stonebrook Private's TNGX Position: Q1 2025 in Review

Stonebrook Private sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 10,992 shares — an estimated $34K sold.

Stonebrook Private first reported a position in TNGX in Q4 2024 and held it in 1 quarter. The position peaked at $34K in Q4 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Stonebrook Private reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stonebrook Private sold 10,992 Tango Therapeutics shares in Q1 2025, an estimated $34K.
  • Stonebrook Private first reported a position in Tango Therapeutics in Q4 2024 and held it in 1 quarter.
  • Stonebrook Private's Tango Therapeutics position peaked at $34K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Stonebrook Private's 13F filing for Q1 2025, filed 30 Apr 2025.